Viral inactivated biological mixture
AssigneeOmrix Biopharmaceuticals Ltd.
InventorsLior Weissman, Itai Podoler, Israel Nur, Tamara Byk-Tennenbaum
Life of this patent
Estimating the term…
Abstract
The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.
Claims22
A method for preparing a viral-safe biological liquid mixture composition from a biological source, the method comprising the following steps:
- providing the source as a clear solution;
- providing a non-toxic amphiphilic polymer;
- treating the source with a solvent detergent (S/D) to allow viral inactivation;
- treating the source with the amphiphilic polymer at a final concentration of 0.01 to 0.9 mM wherein the clarity of the solution is maintained;
- removing the S/D by contacting the treated source with an hydrophobic interaction chromatography (HIC) resin;
- and
- collecting a material comprising an unbound fraction from HIC;
- wherein the method comprises at least one more orthogonal viral inactivation treatment, thereby obtaining the viral-safe biological liquid mixture composition.
A method for preparing a biological liquid mixture composition from a biological source, the method comprising the following steps:
- providing the source as a clear solution;
- providing PVP and/or HPMC;
- treating the source with a solvent detergent (S/D) to allow viral inactivation;
- treating the source with the PVP and/or HPMC at a final concentration of 0.01 to 0.9 mM wherein the clarity of the solution is maintained;
- removing the S/D by contacting the treated source with an hydrophobic interaction chromatography (HIC) resin;
- and
- collecting a material comprising an unbound fraction from HIC.
A method for removing solvent-detergent (S/D) from a biological source comprising S/D, the method comprises the steps of:
- providing the source as a clear solution;
- providing an amphiphilic polymer;
- treating the source with S/D and with the amphiphilic polymer at a final concentration of 0.01 to 0.9 mM wherein the clarity of the solution is maintained;
- removing the S/D from the biological source by contacting the treated source with an hydrophobic interaction chromatography (HIC) resin;
- and
- collecting a material comprising an unbound fraction from HIC.
Dependencies are inferred from the claim text.